{"id":46204,"date":"2025-11-10T14:22:08","date_gmt":"2025-11-10T06:22:08","guid":{"rendered":"https:\/\/flcube.com\/?p=46204"},"modified":"2025-11-10T14:22:09","modified_gmt":"2025-11-10T06:22:09","slug":"novo-nordisk-rules-out-higher-bid-for-metsera-as-pfizer-seals-86-25-per-share-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46204","title":{"rendered":"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) confirmed today that it will <strong>not<\/strong> pursue an increased offer to acquire <strong>Metsera, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MTSR:NASDAQ\">NASDAQ: MTSR<\/a>). The decision follows internal reviews that positioned Metsera as a <strong>potential bolt\u2011on<\/strong> rather than a transformational acquisition for Novo\u2019s obesity\u2011diabetes franchise.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-statements\">Key Statements<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mike\u202fDoustdar, CEO, Novo Nordisk:<\/strong> \u201cWe will return to work and focus on our own promising pipeline, accelerating everything while continuing to search for any complementary business\u2011development deals within diabetes and obesity that we find suitable.\u201d<\/li>\n\n\n\n<li><strong>Market View:<\/strong> Analysts note Novo will keep scouting <strong>obesity, diabetes and related comorbidities<\/strong> opportunities, but the company prefers organic growth and selective bolt\u2011on targets.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-metsera-s-revised-merger-agreement\">Metsera\u2019s Revised Merger Agreement<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td><strong>Metsera, Inc.<\/strong> (NASDAQ:\u202fMTSR)<\/td><\/tr><tr><td><strong>Offer Price<\/strong><\/td><td><strong>USD\u202f86.25\u202fper share<\/strong> (USD\u202f65.60 cash + contingent value right (CVR) up to USD\u202f20.65 cash)<\/td><\/tr><tr><td><strong>Comparison<\/strong><\/td><td>Slightly above Novo\u2019s prior proposal of <strong>USD\u202f86.20\u202fper share<\/strong><\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>\u2248\u202fUSD\u202f10\u202fbillion<\/strong> (including CVR upside)<\/td><\/tr><tr><td><strong>Closing Timeline<\/strong><\/td><td>Expected Q1\u202f2026, subject to regulatory approvals<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Adds Metsera\u2019s <strong>obesity\u2011focused pipeline<\/strong> to Pfizer\u2019s expanding metabolic portfolio, enhancing scale in a high\u2011growth therapeutic area.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novo Nordisk:<\/strong> By declining to raise its bid, Novo signals confidence in its <strong>own pipeline<\/strong> (e.g., next\u2011gen GLP\u20111 candidates) and a disciplined M&amp;A approach focused on <strong>high\u2011impact bolt\u2011ons<\/strong>.<\/li>\n\n\n\n<li><strong>Pfizer:<\/strong> The acquisition gives Pfizer a <strong>fast\u2011track entry<\/strong> into next\u2011generation obesity therapeutics, complementing its existing <strong>weight\u2011loss portfolio<\/strong> (e.g., Wegovy). The CVR structure aligns upside potential with Metsera\u2019s future milestones.<\/li>\n\n\n\n<li><strong>Market Reaction:<\/strong> Novo\u2019s shares were <strong>flat<\/strong> after the announcement, while Pfizer\u2019s stock rose <strong>\u2248\u202f1.8\u202f%<\/strong> on the news, reflecting investor approval of the strategic fit.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the parties\u2019 strategic intentions, deal terms, and market impact. Actual results may differ due to risks including regulatory approvals, integration challenges, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) confirmed today that it will not pursue an increased offer&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,4364,4365,148,860,863,309],"class_list":["post-46204","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-metsera","tag-nasdaq-mtsr","tag-novo-nordisk","tag-nyse-nvo","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) confirmed today that it will not pursue an increased offer to acquire Metsera, Inc. (NASDAQ: MTSR). The decision follows internal reviews that positioned Metsera as a potential bolt\u2011on rather than a transformational acquisition for Novo\u2019s obesity\u2011diabetes franchise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46204\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) confirmed today that it will not pursue an increased offer to acquire Metsera, Inc. (NASDAQ: MTSR). The decision follows internal reviews that positioned Metsera as a potential bolt\u2011on rather than a transformational acquisition for Novo\u2019s obesity\u2011diabetes franchise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46204\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T06:22:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T06:22:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal\",\"datePublished\":\"2025-11-10T06:22:08+00:00\",\"dateModified\":\"2025-11-10T06:22:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002.webp\",\"keywords\":[\"Biotech\",\"Finance\",\"Metsera\",\"NASDAQ: MTSR\",\"Novo Nordisk\",\"NYSE: NVO\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46204#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46204\",\"name\":\"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002.webp\",\"datePublished\":\"2025-11-10T06:22:08+00:00\",\"dateModified\":\"2025-11-10T06:22:09+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) confirmed today that it will not pursue an increased offer to acquire Metsera, Inc. (NASDAQ: MTSR). The decision follows internal reviews that positioned Metsera as a potential bolt\u2011on rather than a transformational acquisition for Novo\u2019s obesity\u2011diabetes franchise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46204\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46204#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) confirmed today that it will not pursue an increased offer to acquire Metsera, Inc. (NASDAQ: MTSR). The decision follows internal reviews that positioned Metsera as a potential bolt\u2011on rather than a transformational acquisition for Novo\u2019s obesity\u2011diabetes franchise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46204","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal","og_description":"Novo Nordisk A\/S (NYSE: NVO) confirmed today that it will not pursue an increased offer to acquire Metsera, Inc. (NASDAQ: MTSR). The decision follows internal reviews that positioned Metsera as a potential bolt\u2011on rather than a transformational acquisition for Novo\u2019s obesity\u2011diabetes franchise.","og_url":"https:\/\/flcube.com\/?p=46204","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-10T06:22:08+00:00","article_modified_time":"2025-11-10T06:22:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46204#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46204"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal","datePublished":"2025-11-10T06:22:08+00:00","dateModified":"2025-11-10T06:22:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46204"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46204#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002.webp","keywords":["Biotech","Finance","Metsera","NASDAQ: MTSR","Novo Nordisk","NYSE: NVO","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46204#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46204","url":"https:\/\/flcube.com\/?p=46204","name":"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46204#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46204#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002.webp","datePublished":"2025-11-10T06:22:08+00:00","dateModified":"2025-11-10T06:22:09+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) confirmed today that it will not pursue an increased offer to acquire Metsera, Inc. (NASDAQ: MTSR). The decision follows internal reviews that positioned Metsera as a potential bolt\u2011on rather than a transformational acquisition for Novo\u2019s obesity\u2011diabetes franchise.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46204#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46204"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46204#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002.webp","width":1080,"height":608,"caption":"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46204#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46204"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46204\/revisions"}],"predecessor-version":[{"id":46209,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46204\/revisions\/46209"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46208"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}